How India Exports Antidandruff to the World

Antidandruff products are regulated by the U.S. Food and Drug Administration (FDA) as over-the-counter (OTC) drugs. According to 21 CFR § 358.750, these products must comply with specific labeling requirements, including statements of identity and indications for use. (law.cornell.edu)

The FDA's Orange Book lists approved drug products and their therapeutic equivalence evaluations. A search of the Orange Book reveals that there are several approved Abbreviated New Drug Applications (ANDAs) for antidandruff products, indicating the presence of generic alternatives in the market. However, specific details regarding the number of approved ANDAs and recent approvals are not readily available in the provided sources.

Given that antidandruff products are classified as OTC drugs, they are not typically subject to import alerts unless specific safety concerns arise. The regulatory pathway for these products involves compliance with the FDA's OTC Monograph system, which outlines acceptable active ingredients, dosages, formulations, and labeling requirements.

Considering the limited number of active Indian exporters (four) and the total export value of $0.0M USD from 2022 to 2026, it appears that Indian antidandruff products have a minimal presence in the U.S. market. This suggests potential opportunities for Indian manufacturers to expand their footprint by ensuring compliance with FDA regulations and exploring market entry strategies.

In the European Union (EU) and the United Kingdom (UK), antidandruff products are generally classified as cosmetic products. As such, they must comply with the EU Cosmetics Regulation (EC) No 1223/2009 and the UK Cosmetics Regulation, respectively. These regulations require that products be safe for human health when used under normal or reasonably foreseeable conditions.

Manufacturers must ensure that their products meet Good Manufacturing Practice (GMP) requirements, as outlined in ISO 22716. Additionally, a Product Information File (PIF) must be maintained, containing details such as product description, safety reports, and manufacturing methods.

Given that the UK has left the EU, manufacturers must ensure compliance with both EU and UK regulations when exporting antidandruff products to these markets. This includes appointing a Responsible Person (RP) within the respective jurisdictions to oversee compliance and product safety.

Antidandruff products are not listed in the World Health Organization's (WHO) Model List of Essential Medicines, as they are generally considered non-essential for basic healthcare. Consequently, they are not subject to the WHO Prequalification Programme, which primarily focuses on essential medicines.

However, antidandruff products must comply with relevant pharmacopoeial standards to ensure quality and safety. These standards may include the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), depending on the target market. Compliance with these standards ensures that products meet the necessary quality specifications for active ingredients, excipients, and finished products.

In India, antidandruff products are classified as cosmetics under the Cosmetics Rules, 2020, issued by the Central Drugs Standard Control Organisation (CDSCO). These rules outline the regulatory requirements for the manufacture, import, and sale of cosmetic products in India.

As cosmetics, antidandruff products are not subject to the Drug Price Control Order (DPCO) or the National Pharmaceutical Pricing Authority (NPPA) ceiling price regulations, which apply to scheduled drugs. However, manufacturers and exporters must obtain a No Objection Certificate (NOC) from the CDSCO for the export of cosmetic products, ensuring that they meet the necessary safety and quality standards.

Antidandruff products, particularly those containing well-established active ingredients, are generally not protected by patents, allowing for generic competition. However, specific formulations, delivery systems, or novel combinations may be patented, granting exclusivity to the patent holder for a certain period. Manufacturers should conduct thorough patent searches to ensure that their products do not infringe on existing patents, especially when entering new markets.

In November 2023, the Federal Trade Commission (FTC) challenged more than 100 patents listed in the FDA's Orange Book as improperly or inaccurately listed, affecting various drug products, including inhalers and autoinjectors. While this action did not specifically target antidandruff products, it underscores the importance of accurate patent listings and the potential for regulatory scrutiny.

In September 2023, the FTC issued a policy statement warning pharmaceutical companies against the improper listing of patents in the FDA's Orange Book, highlighting the agency's commitment to promoting competition and preventing anticompetitive practices.

These developments emphasize the need for manufacturers to ensure compliance with patent listing requirements and to be vigilant about regulatory changes that may impact market access and competition.

India's pharmaceutical industry, including the production of antidandruff medications, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of KSMs used in Indian pharmaceutical manufacturing are sourced from China, creating a significant dependency. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and quality control issues. For instance, in February 2025, the U.S. FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP), highlighting ongoing quality concerns.

To mitigate these risks, the Indian government has initiated the Production Linked Incentive (PLI) scheme aimed at reducing import dependence by promoting domestic manufacturing of critical APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to produce essential molecules like Penicillin G and Clavulanic Acid, which are vital for antibiotic production. These efforts are expected to reduce India's import dependence on key pharmaceutical ingredients by half.

Our proprietary trade data indicates that the top five exporters of antidandruff products from India account for 47.6% of the market share, with EDGES MEDICARE PRIVATE LIMITED leading at 30.9%. This concentration poses a single-source risk, as disruptions affecting these key suppliers could significantly impact the supply chain. The PLI scheme, launched in 2020, aims to diversify the supplier base by incentivizing new entrants and expanding existing capacities. However, as of March 2026, the full impact of this initiative on reducing supplier concentration remains to be seen.

Recent geopolitical events have further strained the pharmaceutical supply chain. In February 2026, Iran's blockade of the Strait of Hormuz disrupted global shipping routes, leading to increased transit times and shipping costs. This blockade has particularly affected the transportation of oil and gas, causing energy prices to surge and impacting manufacturing costs across various industries, including pharmaceuticals. (lemonde.fr) Additionally, the Red Sea conflict has posed risks to the supply of key pharmaceutical ingredients and chemicals, including APIs shipped from Asia to the U.S. and Europe. (pharmasource.global) These disruptions underscore the vulnerability of the supply chain to geopolitical tensions and the need for strategic risk mitigation measures.

• Diversify API and KSM Sources: Reduce dependency on a single country by sourcing APIs and KSMs from multiple regions to mitigate risks associated with geopolitical tensions and trade disputes.

• Enhance Domestic Manufacturing: Accelerate the implementation of the PLI scheme to boost domestic production of critical APIs and KSMs, thereby reducing reliance on imports.

• Strengthen Supplier Relationships: Develop strategic partnerships with multiple suppliers to ensure a more resilient supply chain and reduce single-source risks.

• Monitor Geopolitical Developments: Establish a dedicated team to continuously monitor geopolitical events and assess their potential impact on the supply chain, enabling proactive risk management.

• Invest in Supply Chain Resilience: Implement advanced analytics and risk assessment tools to identify vulnerabilities and develop contingency plans for potential disruptions.

RISK_LEVEL: MEDIUM